• Citigroup maintains a Neutral rating for GSK PLC (NYSE:GSK), raising its price target following a significant stock rally.
• GSK's full-year 2025 earnings per share exceeded consensus by 2%, with 2026 guidance meeting expectations.
• Despite slight earnings forecast adjustments, GSK's long-term earnings are considered stable, supported by strategic moves and leadership focus on R&D and business development.

GSK PLC (NYSE:GSK) is a global healthcare company that focuses on pharmaceuticals, vaccines, and consumer healthcare products. It competes with other major pharmaceutical companies like Pfizer and Johnson & Johnson. On February 9, 2026, Citigroup maintained its Neutral rating for GSK, advising investors to hold their positions. At that time, GSK's stock price was $58.77.

Citi raised GSK's price target from 1,900 GBp to 2,250 GBp, equivalent to £22.50. This increase follows a significant rally in GSK's stock, driven by improved investor sentiment. GSK's full-year 2025 earnings per share exceeded consensus by 2%, and its 2026 guidance aligns with expectations, as highlighted by Proactive Investors.

Despite trimming its 2026 and 2027 earnings forecasts by 1% to 2% due to foreign exchange challenges and vaccine assumptions, Citi believes GSK's long-term earnings remain stable. The recent rise in GSK's shares is attributed to consistent operational performance and increased confidence in strategic execution.

Investors have reacted positively to the new CEO, Luke Miels, who is focusing on accelerating research and development and pursuing lower-risk business development. Citi also noted recent strategic moves, such as the deal with RAPT Therapeutics, and management's efforts to support a £40 billion revenue target.

Currently, GSK's stock price is $58.92, reflecting a decrease of 2.175% or $1.31. The stock has traded between $58.61 and $59.94 today, with a market capitalization of approximately $118.8 billion. GSK's trading volume today is 5,283,039 shares, indicating active investor interest.